

Original Research Article

Prevalence of ~~carbapenem resistant~~ carbapenem-resistant hospital acquired infections and ~~its~~ their antimicrobial susceptibility pattern in a tertiary care hospital

ABSTRACT

Background: The emergence of ~~antimicrobial-resistant~~ antimicrobial-resistant bacteria has become a public threat, creating a burden on medical care in hospitals. ~~Carbapenem resistant~~ Carbapenem-resistant organisms are a source of both ~~community acquired~~ community-acquired and ~~healthcare-acquired~~ healthcare-acquired infection that poses a substantial hazard to public health. This study aimed to conclude the prevalence of carbapenem resistance ~~gram-negative~~ gram-negative bacteria from a clinical specimen at Index ~~medical~~ Medical college-Indore.

Methodology: This study ~~was~~ was conducted in the Department of Microbiology, at Index Medical ~~college~~ College, Indore, between January 2020 and January 2022. The isolates were subjected to antimicrobial susceptibility tests by Kirby Bauer's disk diffusion test most of the isolates were resistant to ~~beta-lactams~~ beta-lactam drugs, cephalosporin's and ~~amino glycosides~~ aminoglycosides. These isolates were further ~~conformed~~ confirmed by phenotypic detection using ~~the~~ Modified Hodge test, Modified carbapenem Inactivation, Combined disc diffusion test, and Double Disk Synergy.

Results: The percentage distribution of ~~health-associated~~ health-associated infection show ~~the~~ highest resistance in both urinary tract and respiratory tract infection, followed by skin & soft tissue infection, and least in septicemia and other ~~health-associated~~ health-associated infection. ~~Highest~~ The highest percentage of resistance was seen in ~~the~~ age group between 21-30 and ~~the~~ least in less than 10 years with ~~a~~ statistical significance of p -value=.00001. The most common isolates recover was E.coli in Enterobacterials and in Non fermenter it was Pseudomonas aeruginosa and Acientobacter. The sensitivity of MHT, mCIM, CDDT, ~~and~~ DDST within CI 95% were 74%, 95%, 84%, ~~and~~ 95% respectively. The overall prevalence of carbapenem resistance is 17.75%.

Conclusion: The production of carbapenemase is the major mechanism underlying carbapenem resistance around the world and represents a great health concern. More knowledge is needed to control resistant genes and resistant organisms and their dissemination. There is an urgent need for ~~a~~ global collaboration to plan valid strategies to prevent the spread of carbapenemase and the development of new antimicrobial molecules.

Keywords: Carbapenem resistance; Metallo~~beta-lactamase~~ beta-lactamase; Antimicrobial susceptibility; Phenotypic detection; Nosocomial Infections

1. INTRODUCTION

The most versatile family of ~~beta-lactamase~~~~beta-lactamase~~, are carbapenemase [1] Carbapenemase, enzymes hydrolyze almost all ~~beta-lactams~~~~beta-lactams~~ and does not work against inhibitor. [2, 3]. ~~Carbapenem-resistant gram-negative~~~~Carbapenem-resistant gram-negative~~ bacteria are difficult to treat infections in hospitalized patients. It leads to high mortality [4] and ~~are-is~~ the last resort for salvage treatment of ~~multidrug-resistant~~~~multidrug-resistant~~ ~~Gram-negative~~~~Gram-negative~~ bacteria. Carbapenem becomes a life threatening ~~threatening~~ to the survival of ~~critical-critically~~ ill patients, with 50% mortality [5]. There is an ~~increase-increased~~ alert of prevalence in ~~multidrug-resistant~~~~multidrug-resistant~~ organism which causes serious nosocomial infections. Globally ~~Carbapenem-resistant~~~~Carbapenem-resistant~~~~gram-negative~~~~gram-negative~~ organisms are the main cause of nosocomial infection. [6]. This is a ~~cross-sectional~~~~cross-sectional~~ study performed to determine the prevalence of ~~carbapenem-resistant~~~~Gram-negative~~~~carbapenem-resistant~~ ~~Gram-negative~~ bacilli isolated from patients admitted in wards tertiary care ~~hospital-hospitals~~ in Central India. We compared different methods for ~~the~~ detection of carbapenemase and Metallo~~beta-lactamase~~~~beta-lactamase~~ (MBL).

2. MATERIAL AND METHODS

~~This~~ ~~This~~ study is a cross ~~sectional~~~~sectional~~ study, conducted in ~~the~~ Bacteriology section of ~~the~~ microbiology laboratory of Index Medical College, Hospital and Research Center, Indore (M.P.) from January 2020 to January 2022. A total of 246 clinical samples from ~~a~~ patient admitted for more than 48 hours were collected from ~~the~~ different clinical department.

2.1 Antibiotic Susceptibility Testing

Antibiotic susceptibility testing of ~~Gram-negative~~~~Gram-negative~~ isolates was done by Kirby Bauer's disc diffusion method using the following antibiotics Imipenem, Meropenem, ~~Ertapenem~~~~Ertapenem~~ Ciprofloxacin, Amikacin, ~~Piperacillin~~~~Piperacillin~~/tazobactam, Cefazidime, Gentamicin, Ampicillin, Cefazolin, Tobramycin, Tigecycline Cefepime, Ceftriaxone, ~~Amoxycylav~~~~Amoxiclav~~, Cefotaxime, Colistin in Mueller Hinton Agar according to CLSI guidelines (7).

2.2 Phenotypic detection of carbapenem and Metallo β lactamase production

The detection was done by ~~the~~ Modified Hodge test [8], Modified carbapenem Inactivation Method [8], for phenotypic detection of MBL, Combined disc diffusion test [9] and Double Disk Synergy test (10) was done.

3. RESULTS

A total of 246 clinical samples were collected during the study period from Jan 2020 to Jan 2022 from various clinical departments from which 129 (52.43%) were positive for different isolates. From the 129 positive isolates, 22 (8.94%) were ~~gram-positive~~~~gram-positive~~ bacteria and 107 (43.49%) were ~~gram-negative~~~~gram-negative~~ bacilli. From 107 gram negative isolates, 80.37% were *Enterobacterales* and 19.62% were non-fermenter. *E.coli* (32.55%) followed by, *Klebsiella pneumoniae* (17.5%), *Citrobacter species* and *Pseudomonas aeruginosa* (8.52), *Acinetobacter Species* 7.55%, *Proteus mirabilis* 4.56% and *Enterobacter species* 3.87%.

On performing Kirby Bauer disc diffusion method 59.09% ~~of~~ ~~male~~ ~~patient~~~~patients~~ were sensitive and 63.15% were resistant to carbapenem where as 40.90% were sensitive and 36.84% were resistant to carbapenem. The statistical analysis of p-value = 0.00001 for both ~~carbapenem-resistant~~~~carbapenem-resistant~~ and carbapenem sensitive as shown in Table 1

Table 1 Gender-wise distribution of carbapenem resistant and carbapenem sensitive isolates

Gender	Carbapenem resistant	Carbapenem sensitive	Total	p-value
Male	12(63.15)	52(59.09)	64(59.81)	0.00001
Female	7(36.84)	36(40.90)	43(40.18)	0.00001
	19	88	107	

Formatted: Font: 8 pt

Comment [tb1]: Please explain why the total number of resistance isolates was 107 and not 129 ??? and why you used bacterial gram-negative only in this table.

Percentage distribution of carbapenem-resistant drug show 21% resistance by Imipenem and Meropenem followed by Etrapanem 11%. In coexisting resistance were was seen as Meropenem plus Etrapanem, Imipenem plus Etrapanem 5% each, Imipenem plus Meropenem 11% and 26% were resistant to all three drugs shown in Fig 1. The prevalence of carbapenem resistance was 17.75%. Percentage-The percentage of sensitivity of Imipenem was 79%, Meropenem 79%, and Etrapanem 89% respectively.




Fig 1 Resistance pattern of carbapenem drugs

The antimicrobial sensitivity pattern highest sensitivity of Colistin (89%) followed by Tigecycline (58%), Amikacin (21%), Ciprofloxacin and Amoxyclav (16%) Ampicillin, Cefazolin, Tobramycin, Piperacillin/Piperacillin/Tazobactam, Levofloxacin (11%), Cefepime and Gentamicin (5.2%), Cefotaxime, Ceftriaxone and Ceftazidium with no sensitivity. Ceftriaxone, Cefotaxime and Ceftazidium show 100% resistance followed by Gentamicin and Cefepime (95%), Ampicillin, Cefazolin, Levofloxacin, Tobramycin, Piperacillin/piperacillin/tazobactam (89%), Ciprofloxacin and Amoxyclav (84%), and least resistance was observed in Tigecycline (42%) Fig.2




Fig 2.Antimicrobial susceptibility test

Highest percentage of nosocomial infection was seen in urinary tract infection (65.4%) followed by skin & soft tissue infection (15.88%), respiratory tract infection (10.28%), (4.67%) septicemia and least infection was seen in other health associated infection (3.73%). The percentage distribution of health associated infection has highest carbapenem resistance in urinary tract and respiratory tract infection account of (31.57%) followed by skin & soft tissue infection (15.78%), and least about (10.52%) was seen in septicemia and other health associated infection. Table 2

Table 2 Types of hospital acquired infection in relation to gram negative and gram positive carbapenem resistance

Type of HAI	Positive Sample N (%)	GNR N(%)	CRGNR N(%)	p-value
Urinary tract infection	75(58.10)	70(65.4)	6(31.57)	.000001
Skin & Soft tissue infection	26(20.10)	17(15.88)	3(15.78)	.000943
Septicemia	8(6.20)	5(4.67)	2(10.52)	.004893
Respiratory tract infection	12(9.30)	11(10.28)	6(31.57)	.001058
Other HAI's	8(6.20)	4(3.73)	2(10.52)	.024271

Comment [tb2]: This table for gram positive and gram negative isolate please note that

GNR-Gram Negative Bacilli, CRGNR-Carbapenem Resistant Gram Negative Bacilli

Age wise distribution accounts for sample collected from patients have highest percentage of 23.17% age group 41-50yrs, followed by 21.95% , 31-40 yrs 19.1%, 21-30 yrs ,15.44% more than 50yrs, 32 (13%) and 7.31% age less than 10yrs. In overall age group positive isolates were observed in age group 21-30yr , 28.68%, followed by 18.6%% (31-40yrs), 17.05%(10-20yrs), 15.5% more than 50yrs, 12.43%(41-50yrs) and 7.75% less than 10 yrs. The overall gram negative bacilli were highest in age group between 21-30 (28.9%) followed by 31-40 (20.5%), 10-20 (15.8%), more than 50 (15.3%), 41-50 (13.0%), less than 10 years (6.5%) respectively. Overall carbapenem resistance is highest in age group 21-30 (42.1%) followed by 10-20 age group (21.05), more than 31 (10.52%) and less than 10 yrs (5.26%) Overall p-value= .000857. Table 3

Age group (in Years)	Total sample N(%)	Positive isolates N(%)	GNR N(%)	CRGNR N(%)	p-value
less than 10	18(7.31)	10(7.75)	7 (6.5)	1(5.26)	.016157
10_20	32(13)	22(17.05)	17(15.8)	4(21.05)	.000538
21-30	47(19.1)	37(28.68)	31(28.9)	8(42.1)	.00001
31-40	54(21.95)	24(18.6)	22(20.5)	2(10.52)	.00001
41-50	57(23.17)	16(12.43)	14(13.0)	2(10.52)	.0001214
more than 50	38(15.44)	20(15.5)	16(15.3)	2(10.52)	.000159

Table 3 Age wise distribution of isolates

Gram negative bacteria were isolated from the different department; the maximum isolates were medicine 51% followed by surgery 21%, intensive care unit 14%, obstetrics & gynaecology 7%, and pediatric 6%. Among the different department the maximum carbapenem resistant gram negative bacteria was present in medicine 31.57% which was followed by surgery 26.31% , intensive care unit 21.05% and obstetrics & gynaecology and Pediatric showing

the same percentage of resistance 10.52% .. Among the gram-negative bacteria, the maximum number of bacteria were isolated from Urine 65.4% followed by Pus 15.8%, Endotracheal aspirate 6.5%, Blood 4.6%, Sputum and other HAI's 3.7%. Among them maximum carbapenem resistant GNR were isolated from Urine 31.5% followed by Endotracheal aspirate 21%, Pus 15.7% and 10.5% Blood, Sputum and other health associate infection (Table 4) The statistical significant difference of p-value=0.0001.

Comment [tb3]: Please used full name then used abbreviations

Department	Blood	Urine	Pus	Sputum	ET	Other HAI's	GNR
Medicine	0	53	0	2	0	0	55
Surgery	0	8	12	1	0	2	23
Obstetrics & Gynaecology	0	4	3	0	0	1	8
Pediatric	4	0	1	0	0	1	6
Intensive care unit	1	5	1	1	7	0	15
Total GNR	5(4.6)	70(65.4)	17(15.8)	4(3.7)	7(6.5)	4(3.7)	107
CRGNR	2(10.5)	6(31.5)	3(15.7)	2(10.5)	4(21.0)	2(10.5)	19

Comment [tb4]: Total isolates was 126 while all isolate was 129 where the missing three isolate

Table 4 Department wise distribution of GNR and CRGNR
 ET- Endotracheal Aspirate, HAI- Hospital associated infection, GNR-Gram negative rod,
 CRGNR- Carbapenem resistant gram negative Rods

Among the nosocomial infection, the maximum number of organisms were isolated from urinary tract infection which include *E.coli* 423% followed by *Klebseilla pneumoniae* 20%, *Citrobacter species* 13%, *Pseudomonas aeruginosa* 10%, *Enterobacter species* 8%, *Proteus species* 6 % and *Acientobacter species* 1%. Second highest infection is caused by skin soft tissue infection *E.coli* contribute the highest prevalence in causing soft & skin tissue infection species and *Pseudomonas aeruginosa* 6% with no isolates from *Enterobacter species* and *Acientobacter species* were isolated. Among the respiratory tract infection accounts for the third highest infection, responsible organisms include *Acientobacter species* 63% followed by *Klebseilla pneumoniae* 18%, *E.coli* and *Proteus species* each 9%. Fourth highest nosocomial infection was septicemia and other hospital-associated infection, which was caused by 60%, *Klebseilla pneumoniae* followed by *E.coli* and *Pseudomonas aeruginosa* 20%, each respectively. Among the least nosocomial findings were from other hospital-associated infections in which 50% of isolates were from *Pseudomonas aeruginosa* and *Acientobacter Species*. Carbapenem resistance in *E.coli* and *Klebseilla pneumoniae* 21.5% were the highest among the *Enterobacterials*. Least carbapenem resistance was seen among *Enterobacter species* and *Proteus species* 5.26%. Carbapenem resistance among non-fermenter *Pseudomonas aeruginosa* and *Acientobacter species* were the same about 15.7%.

Among the phenotypic methods for the detection of Carbapenem were done by MHT and mCIM. For Metallo beta lactamase detection was done by CDDT and DDST. The sensitivity of MHT, mCIM, CDDT, and DDST within CI 95% were 74%, 95%, 84%, 95% respectively. The overall prevalence of carbapenem resistance is 17.75%.

5. DISCUSSION

The overall prevalence of carbapenem-resistant in this study was 17.75%. Similarly the study was found with the prevalence of 18%, 17%, 17.32% respectively [11, 12, and 13]. In contrast Mulla S et al [14] and Mate et al. [15] show a prevalence of 30%. The prevalence of carbapenem resistance in different parts of India

varies from 14-69%. The ~~prevalence~~ ~~prevalence~~ of ~~carbapenem-resistant~~ ~~carbapenem-resistant~~ from various countries was found to be around 36% in Egypt [16], 13.6% and 37.9% in Iran [17, 18], 56% in Pakistan [19], 24.6% in China [20], 19% in Algeria [21], 2.82% in Turkey [22], 86.3% in Tunis [23], 5.99% in Morocco [24] and 2.9% in Ghana [25], 14.6%, 65%, 30%, in India [26] 27.1% in Ethiopia [27], 0.22% in Germany [28].

On performing Kirby Bauer disc diffusion method 59.09% of male patient were sensitive and 63.15% were resistant to carbapenem where as 40.90% were sensitive and 36.84% were resistant to carbapenem with the statistical significance of p -value 0.00001; which was similar to T.V. Parimala 50.90% [29] Satyajeet K. Pawar et al., 65.3% [30] and Namitha Thomas [31]

In this study gram negative bacilli were highest in age group between 21-30 (28.9%), followed by 31-40 (20.5%), 10-20 (15.8%), more than 50 (15.3%), 41-50 (13.0%), less than 10 years (6.5%) respectively. Overall carbapenem resistance is highest in age group 21-30 (42.1%) similar to Namitha Thomas (31) reported highest carbapenem resistance in age group between 21-40 years (36.25%), which was followed by 10-20 age group (21.05%), more than 31 (10.52%) and less than 10 yrs (5.26%) Overall p -value = .000857. In contrast study by Pawar SK et al. [32] and Monika Saini et al [33] show highest percentage of age 41-50 years.

In our study the maximum organisms were isolated from urinary tract infection, followed by skin soft tissue infection, respiratory tract infection, septicemia and least nosocomial findings were from other hospital associated infections. Similar findings were from Urinary tract infection ~~from~~. [34, 35]

Carbapenem resistance in *E.coli* and *Klebsiella pneumoniae* (21.5%) were highest among the *Enterobacterials*. Least carbapenem resistance was seen among *Enterobacter species* and *Proteus species* (5.26%). Carbapenem resistance among non-fermenter *Pseudomonas aeruginosa* and *Acinetobacter Species* were same about 15.7%. A similar study was found which show *E.coli* and *Klebsiella pneumoniae* to be the commonest cause of infection. [36,37] In contrast the most prevalent bacteria reported were *Klebsiella species*, *A. baumannii*, followed by *E. coli* and *P. aeruginosa* [17]. There is a statistical significant difference of $p < 0.05$ in the prevalence of ~~gram-negative~~ ~~gram-negative~~ bacteria and carbapenemase-resistant isolates recovered from different types of specimens.

Among the different ~~department~~ ~~departments~~ the maximum carbapenem resistance ~~were~~ ~~were~~ present is medicine 31.57% which was followed by surgery 26.31%, intensive care unit 21.05% and obstetrics & ~~gynaecology~~ ~~gynecology~~ and pediatric showing the same percentage of resistance 10.52%. In contrast to our study it shows the maximum number of isolates from the Surgery ward 22% followed by 19% medicine ward, 18% orthopedic ward, 15% MICU and 12% Pediatric ward, 14% isolates obtained from other wards and ICUs. [38, 39]

Among maximum ~~carbapenem-resistant~~ ~~carbapenem-resistant~~ GNR were isolated from Urine 31.5% followed by Endotracheal aspirate 21%, Pus 15.7% and 10.5% Blood, Sputum, and other health associated infection. ~~Similar-A similar~~ study by Lim et al. [40] it shows a high percentage of resistance in urine 25.9%, lower respiratory tract 14.3% and blood 17%. In the study of Pano Pardo et al [41] and Seibert et al. [42] show these bacteria are commonly isolated from bronchial alveolar lavage (BAL), urine, and blood.

In our study it shows the highest sensitivity of Colistin 89% and 3rd generation cephalosporine show 100% resistance. A study showed that many carbapenemase producers are

Comment [tb5]: Please note that these percentages were depend on the number of isolated in the specific age groups and not for all number of isolate

susceptible in vitro to [the glycolcycilline group](#) (Tigecycline), but there is rapid increase [in resistance to this drug](#) [43]. Morrill et al [44], reported monotherapy is not effective against infection caused by ~~carbapenem-resistant~~[carbapenem-resistant](#) bacteria.

In our study the highest sensitivity was found in DDST 95% followed by mCIM 95%, CDDT 84%, and MHT 74%, within CI 95% according to Naim H et al(45) also found CDDT 84.81%. In contrast the study by Naim H,et al [45] found sensitivity of MHT, and DDST as 97.41% and 84.81%. In a study by Cury et al.(46),it shows least percentage of 35.5% MHT.

6. CONCLUSION

Our study illustrates the emergence of ~~carbapenem-resistant~~[carbapenem-resistant](#) Gram-negative hospital acquired infection ~~from inpatients~~. To identify the responsible agent that leads to infection in healthcare settings. The common agents were *E.coli*, *Klebseilla pneumoniae*, *Citrobacter species*, *Pseudomonas aeruginosa*, *Enterobacter species*, *Proteus species* and *Acientobacter species*. The recovered isolates show [the prevalence of 17.75%](#) carbapenem resistance to Imipenem, Etrapienem and Meropenem drugs. , the carbapenem resistance is considered as the global alarm for pandemic resistance. As these carbapenem were the last resorts to combat from ~~multidrug-resistant~~[multidrug-resistant](#) organism. Warning signal of MDR, XDR and PDR left with few drugs like Colistin and Tigecycline. In few studies we can see these drugs are also showing resistance.

Formatted: Font: Italic

ETHICAL APPROVAL

The study was approved by Ethics committee MU/MM/BNS/2020/51(a)

REFERENCES

1. Queenan AM, Bush K. Carbapenemases: The versatile beta lactamases. Clin Microbiol Rev 2007;20:440-58.
2. Livermore DM, Woodford N. Carbapenemases: A problem in waiting. Curr Opin Microbiol 2000;3:489-95.
3. Nordmann P, Boulanger AE, Poirel L. NDM , Metallo β lactamase with increased carbapenemase activity fro *Escherichia coli*. Antimicrob Agents Chemother 2012;56:2184-6.
4. Tzouvelekis LS, Markogiannakis A, Psychogiou M, Tassios PT, Daikos GL. Carbapenemases in *Klebsiella pneumoniae* and other Enterobacteriaceae: An evolving crisis of global dimensions. Clin Microbiol Rev 2012;25:682-707.
5. Bourafa N., et al., Molecular characterization of carbapenem-resistant Gram-negative bacilli clinical isolates in Algeria. Infection and drug resistance, 2018. 11:735. <https://doi.org/10.2147/IDR.S150005> PMID: 2984469
6. Karuniawati A., Saharman Y.R., and Lestari D.C., Detection of carbapenemase encoding genes in Enterobacteriaceae, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* isolated from patients at Intensive Care Unit Cipto Mangunkusumo Hospital in 2011 Acta Med Indones, 2013. 45(2):101-6. PMID: 23770789.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; CLSI document M100-S28. Wayne PA: Clinical and Laboratory Standards Institute; 2018
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; CLSI document M100-S28. Wayne PA: Clinical and Laboratory Standards Institute; 2018.

9. Pournaras S, Zarkotou O, Poulou A, Kristo I, Vrioni G, Themeli-Digalaki K, et al. A combined disk test for direct differentiation of carbapenemase-producing enterobacteriaceae in surveillance rectal swabs. *J Clin Microbiol.* 2013;51(9):2986-90.
10. Dheepa Muthusamy & Appalaraju Boppe. Phenotypic Methods for the detection of various Betalactamases in Carbapenemase resistant isolates of *A.baumannii* in a Tertiary care Hospital in a south India. *India. J of Clin Diagnostic Research.* 2012;6(6):.970-73.
11. Haji SH, Aka STH, Ali FA. Prevalence and characterisation of carbapenemase encoding genes in multidrug-resistant Gram-negative bacilli. *PLoS One* 2021; 16: e0259005. *Microbiology and Applied Sciences* 5(12): 18–22. <http://dx.doi.org/10.20546/ijcmas.512.003> (December 6, 2019).
12. Sreeja K. Vamsi, Rama S. Moorthy, Mary N. Hemilamma, Rama B. Chandra Reddy, Deepak J. chanderakant. Phenotypic and genotypic detection of carbapenemase production among gram negative bacteria isolated from hospital acquired infections. *Saudi Med J* 2022; 43 (3), 236-243 doi: 10.15537/smj.2022.43.3.20210809
13. Gupta E, Mohanty S, Sood S, et al. Emerging resistance to carbapenems in a tertiary care hospital in north India. *Indian J Med Res.* 2006.124(1),95– 98.
14. Mulla S, Charan J, Panvala T. Antibiotic sensitivity of Enterobacteriaceae at a tertiary care center in India. *Chron Young Sci* 2011.2, 214-18.
15. Mate, P. H., Devi, K. S., Devi, K. M., Damrolien, S., Devi, N. L., & Devi, P. P. Prevalence of Carbapenem Resistance among Gram - Negative Bacteria in a Tertiary Care Hospital in North - East India. *IOSR Journal of Dental and Medical Sciences*, 2014. 13(12), 56-60. doi:10.9790/0853-131235660.
16. Makharita R.R., et al., Antibiogram and genetic characterization of carbapenem-resistant gram-negative pathogens incriminated in healthcare-associated infections. *Infection and drug resistance*, 2020. 13,3991. <https://doi.org/10.2147/IDR.S276975> PMID: 33177849.
17. Jalalvand K., et al., Evaluation of phenotypic and genotypic characteristics of carbapenemase-producing enterobacteriaceae and its prevalence in a referral hospital in Tehran city. *Iranian journal of pathology*, 2020. 15(2): p. 86. <https://doi.org/10.30699/ijp.2020.111181.2188> PMID: 32215024
18. Shokri D., et al., Resistotyping, phenotyping and genotyping of New Delhi metallo- β -lactamase (NDM) among Gram-negative bacilli from Iranian patients. *Journal of medical microbiology*, 2017. 66(4),402–411. <https://doi.org/10.1099/jmm.0.000444> PMID: 28150578.
19. Ain N.U., et al., High frequency and molecular epidemiology of metallo- β -lactamase-producing gram negative bacilli in a tertiary care hospital in Lahore, Pakistan. *Antimicrobial Resistance & Infection Control*, 2018. 7(1): p. 1–9. <https://doi.org/10.1186/s13756-018-0417-y>
20. Jin C., et al., Molecular Characteristics of Carbapenem-Resistant *Enterobacter cloacae* in a Tertiary Hospital in China. *Infection and drug resistance*, 2020. 13: p. 1575. <https://doi.org/10.2147/IDR.S254056> PMID: 32547127.
21. Bourafa N., et al., Molecular characterization of carbapenem-resistant Gram-negative bacilli clinical isolates in Algeria. *Infection and drug resistance*, 2018. 11: p. 735. <https://doi.org/10.2147/IDR.S150005> PMID: 29844691
22. Karabay O., et al., The carbapenem-resistant Enterobacteriaceae threat is growing: NDM-1 epidemic at a training hospital in Turkey. *Annals of clinical microbiology and antimicrobials*, 2016. 15(1): p. 1–6.
23. Kollenda H., et al., Screening for carbapenemases in ertapenem-resistant Enterobacteriaceae collected at a Tunisian hospital between 2014 and 2018. *European Journal of Microbiology and Immunology*, 2019. 9(1): p. 9–13. <https://doi.org/10.1556/1886.2018.00033>.
24. Mahrach Y., et al., Phenotypic and molecular study of carbapenemase-producing Enterobacteriaceae in a regional hospital in northern Morocco. *J Clin Med Sci*, 2019. 3: p. 113.
25. Codjoe, F.S., Detection and characterisation of carbapenem-resistant gram-negative bacilli infections in Ghana. 2016, Sheffield Hallam University. <http://shura.shu.ac.uk/id/eprint/15577>

26. Kaur MGS, Kaur T. Detection of carbapenem-resistant gram-negative bacteria in clinical isolates from a tertiary care hospital. *J BacteriolMycol Open Access*. 2016;2(1):00011.33
27. Devi P. Incidence of carbapenem-resistant nonfermenting gram-negative bacilli from patients with respiratory tract infections among intensive care units. *Int J Res Med Sci*. 2017;3(6):4.
28. Mate PDK, Devi K, Damrolien S, Devi P. Prevalence of carbapenem resistance among Gram-negative bacteria in a tertiary care hospital in north-east India. *IOSR J Dent Med Sci*. 2014;13(12):56–60. doi:10.9790/0853-131235660.
29. T.V. Parimala. (2017). Screening of Carbapenem Resistant Enterobacteriaceae among Nosocomial Isolates: A Study from South India. *Int.J.Curr.Microbiol.App.Sci* 6(4): 460-465.
30. Satyajeet K Pawar et al. Carbapenem resistant Enterobacteriaceae: Prevalence and bacteriological profile in a tertiary teaching hospital from rural western India. *Indian J Microbiol Res*. 2018; 5(3): 342-347.
31. Namitha Thomas and Tarana Sarwat. 2019. Prevalence of Carbapenem Resistant Enterobacteriaceae in A Tertiary Care Hospital. *Int.J.Curr.Microbiol.App.Sci*. 8(11): 1418-1424. doi: <https://doi.org/10.20546/ijcmas.2019.811.166>
32. Pawar SK, Mohite ST, Shinde RV, Patil SR, Karande GS. Carbapenem-resistant Enterobacteriaceae: Prevalence and bacteriological profile in a tertiary teaching hospital from rural western India. *Indian J Microbiol Res*. 2018;5(3):342-347.
33. Monika Saini, Aditya Mishra, Sweta Gupta. Prevalence of Carbapenem Resistance in Gram Negative Bacilli Isolates and Their Antimicrobial Susceptibility Pattern. *Int J Med Res Prof*. 2016; 2(3):28-32.
34. Deepak K Tempe, Jyotsna Agarwal, Kapil Chaudhary, Parin Lalwani, Madhu Sudan Tudu, Upendra Hansdah, Bibhavati Mishra. Carbapenem Resistance Patterns in General Intensive Care Unit of a Tertiary Care Hospital in India. *MAMC Journal of Medical Science* 2015. 1(2) : 85-91.
35. Nair PK. Prevalence of carbapenem resistant Enterobacteriaceae from a tertiary care hospital in Mumbai, India. *J Microbiol Infect Dis*. 2013;03(04):207–10..
36. Habibi S, Wig N, Agarwal S, Sharma S, Lodha R, Pandey R and Kapil A. Epidemiology of nosocomial infections in medicine intensive care unit at a tertiary care hospital in northern India. *Tropical Doctors* 2008; 38: 233–5.
37. Rimrang B., et al., Emergence of NDM-1-and IMP-14a-producing Enterobacteriaceae in Thailand. *Journal of antimicrobial chemotherapy*, 2012;67(11): 2626–2630. .
38. Dipak M. Panjwani, Sucheta J. Lakhani, Sanjay J. Mehta, Kunjan M. Kikani and Khushboo Madaan. 2020. A Study of Hospital Acquired Bacterial Infections and its Antimicrobial Susceptibility Pattern in a Teaching Hospital of Gujarat, India. *Int.J.Curr.Microbiol.App.Sci*. 9(02): 1399-1408. doi: <https://doi.org/10.20546/ijcmas.2020.902.162>
39. Nagaraj S, Chandran SP, Shamanna P, Macaden R (2012). Carbapenem resistance among *Escherichia coli* and *Klebsiella pneumoniae* in a tertiary care hospital in south India. *Indian J Med Microbiol* 30(1): 93-95..
40. Lim, Y.J.; Park, H.Y.; Lee, J.Y.; Kwak, S.H.; Kim, M.N.; Sung, H.; Kim, S.H.; Choi, S.H. Clearance of carbapenemase-producing Enterobacteriaceae (CPE) carriage: A comparative study of NDM-1 and KPC CPE. *Clin. Microbiol. Infect.* 2018, 24, 1104.
41. Pano Pardo, J.R.; Serrano Villar, S.; Ramos Ramos, J.C.; Pintado, V. Infections caused by carbapenemase-producing Enterobacteriaceae: Risk factors, clinical features and prognosis. *Enferm. Infec. Microbiol. Clin.* 2014, 32 (Suppl. S4), 41–48.
42. Seibert, G.; Hörner, R.; Meneghetti, B.H.; Righi, R.A.; Dal Forno, N.L.; Salla, A. Nosocomial infections by *Klebsiella pneumoniae* carbapenemase producing enterobacteria in a teaching hospital. *Einstein* 2014, 12, 282–286.
43. Sader H., Farrell D., Flamm R., Jones R. Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). *Antimicrob Agents Chemother.* 2014.58,2274–2280.
44. Morrill H., Pogue J., Kaye K., LaPlante K. (2015) Treatment options for carbapenem-resistant Enterobacteriaceae infections. *Open Forum Infect Dis* 2: ofv050.

45. Naim H, Rizvi M, Gupta R, Azam M, Taneja N, Shukla I, et al. Drug resistance and molecular epidemiology of carbapenem resistant gram⁻negative bacilli isolates. *J Global Infect Dis* 2018.10,13
46. Cury AP, Andreazzi D, Maffucci M, Caiiffa[®]Junior HH, Rossi F. The modified Hodge test is a useful tool for ruling out *Klebsiella pneumoniae* carbapenemase. *Clinics (Sao Paulo)* 2012.67,1427-31.

UNDER PEER REVIEW